BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASIA

This adverse event was reported 81 times

These drugs are most commonly taken by patients reporting BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASIA:

# Drug Count
0 VENETOCLAX 23
1 AZACITIDINE 20
2 CYCLOPHOSPHAMIDE 17
3 CYCLOPHOSPHAMIDE FOR INJECTION 17
4 CYCLOPHOSPHAMIDE INJECTION, SOLUTION 17
5 DEXAMETHASONE 15
6 DEXAMETHASONE 1.5 MG 15
7 DOXORUBICIN 13
8 AZACITIDINE FOR 11
9 METHOTREXATE SODIUM 11
See all common drugs associated with BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASIA

BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASIA is most prevalent among patients taking these drugs:

# Drug Count Frequency
0 TAGRAXOFUSP 10 0.0186
1 PRALATREXATE 1 0.0015
2 PURIXAN 1 0.0013
3 RYDAPT 2 0.0010
4 DECITABINE 3 0.0007
5 AZACITIDINE 20 0.0007
6 DAUNORUBICIN HYDROCHLORIDE 1 0.0006
7 FEBUXOSTAT TABLETS 40 MG 5 0.0005
8 RASBURICASE 1 0.0004
9 VENETOCLAX 23 0.0004
See all drugs enriched for association with BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASIA

BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASIA is most prevalent among patients taking these drug classes:

# Drug class Count Frequency
0 CD123 Interaction [EPC] 10 0.0186
1 CD38-directed Cytolytic Antibody [EPC] 4 0.0007
2 BCL-2 Inhibitor [EPC] 23 0.0004
3 Cannabinoid [EPC] 1 0.0001
4 Topoisomerase Inhibitor [EPC] 9 0.0001
5 Nucleoside Metabolic Inhibitor [EPC] 31 0.0001
6 Alkylating Drug [EPC] 19 0.0001
7 Proteasome Inhibitor [EPC] 8 0.0001
8 Azole Antifungal [EPC] 7 0.0000
9 Erythropoiesis-stimulating Agent [EPC] 2 0.0000
See all drug classes enriched for association with BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASIA